Our findings suggest that the PD-1/PD-L1 pathway plays a critical role in determining the response to chemotherapy and survival in NSCLC, and that PD-L1 polymorphisms may be predictive of the chemotherapy outcome in NSCLC, which is biologically plausible. This evidence concerns the gene CD274 and non-small cell lung carcinoma.